Lifestyle

Pulmuone Corporate Reports 107.8 Billion Won in U.S. Tofu Sales… Continues Growth with Plant Expansion

Cumulative increase of 16.8% in May Waterpack Tofu Drives Earnings Growth

SIN SOO-JUNG
2026-06-18 08:33:49
[Edaily Reporter SIN SOO-JUNG ] Pulmuone Corporate(017810) The U.S. subsidiary’s cumulative tofu sales for May this year exceeded 100 billion won. The tofu business continues to grow as the expansion of local distribution networks in the U.S. and the increase in production capacity have synergized.

Pulmuone Corporate announced on the 18th that its U.S. subsidiary’s cumulative tofu sales from January through May of this year reached 107.8 billion won, a 16.8% increase compared to the same period last year. Sales rose as tofu sales increased across major retail channels, despite a decline in consumer sentiment due to high inflation.

The product driving this growth is water-pack tofu. Water-pack tofu is packaged with filling water and accounts for approximately 70% of Pulmuone Corporate’s U.S. subsidiary’s total tofu sales. Cumulative sales for this product line through May of this year totaled 79.9 billion won, an increase of about 24% compared to the same period last year.

Securing new sales channels also contributed to the growth in performance. Pulmuone Corporate increased its supply volume of water-pack tofu after securing a major new sales channel last September. The inclusion of its soft tofu in the private label (PL) lines of major local retailers and expanded sales through large discount store channels also contributed to the revenue growth.

High-protein tofu and processed tofu also saw growth. Sales of high-protein tofu rose by more than 13% year-over-year to approximately 19.2 billion won, driven by increased sales at Asian markets and discount stores. Sales of processed tofu reached approximately 8.8 billion won, an increase of over 9% compared to the previous year.

Pulmuone Corporate is also expanding its production capacity to meet growing demand in the U.S. In March, the company completed an expansion of its tofu factory in Ayer, Massachusetts, establishing a “Hyperline” capable of producing 9,000 blocks per hour. As a result, the factory’s production capacity has doubled compared to previous levels. Pulmuone Corporate also plans to complete the expansion of its soft tofu production facilities at its Fullerton, California, plant by the end of the year.

Pulmuone Corporate sells its tofu products at approximately 15,000 stores across the United States, including major retailers such as Walmart, Whole Foods Market, Kroger, Target, and Publix. Its product lineup includes water-packed tofu, high-protein tofu, and processed tofu baked with Western-style seasonings.

Cho Gil-soo, CEO of Pulmuone Corporate USA, stated, “As local consumer trends toward reducing meat consumption and seeking healthier protein sources continue to spread, tofu is rapidly establishing itself as a popular food culture among U.S. consumers.” He added, “Based on our overwhelming product supply capacity—achieved through successful channel diversification centered on major discount stores and the expansion of our production infrastructure—we will further solidify our position as the No. 1 tofu brand in the U.S. market.”

Pulmuone Corporate launched its U.S. tofu business in earnest in 2016 with the acquisition of the U.S. tofu brand Nasoya. The company explained that it has maintained the top market share in the U.S. tofu market for 11 consecutive years through this year, and that its U.S. tofu sales have been setting new annual records every year since 2021.

Economy

Corporation

IT·Science

Economy

Only 8% of Internet Bank Loans Go to Small Business Owners… “The Fourth Internet Bank Should Exceed 50%”

As loans to sole proprietors from the three existing internet-only banks (KakaoBank Corp.(323410), #Kbank, and Toss Bank) remain at around 8% of their total loan portfolio, calls are growing for the f…
2026-08-25 17:44:39

Corporation

Bio Solution Co.,Ltd. Focuses on Managing the “Placebo Group” in DMOAD Trials… What Is the Strategy to Increase the Likelihood of Clinical Success?

Bio Solution Co.,Ltd.(086820)BioSolution is focusing its R&D efforts on clearly demonstrating the difference in efficacy between the treatment group and the placebo group in the clinical trial for “Sp…
2026-08-25 16:20:03